Ignite Creation Date:
2024-05-05 @ 12:00 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00206635
Status:
COMPLETED
Last Update Posted:
2012-11-22
First Post:
2005-09-09
Brief Title:
Betaseron 16-Year Long-Term Follow-Up LTF in Patients With Relapsing-Remitting Multiple Sclerosis
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
A Long-term Follow up of Patients Enrolled in the Pivotal Study of Betaseron Interferon Beta 1b in Relapsing-remitting Multiple Sclerosis
Status:
COMPLETED
Status Verified Date:
2012-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this follow-up study is to look carefully at the long-term course of multiple sclerosis MS and possibly the long-term effects of Betaseron in the patients who were previously enrolled in the original North American study that led to the marketing approval of Betaseron
Detailed Description:
This study has previously been posted by Berlex Inc Berlex Inc has been renamed to Bayer HealthCare Pharmaceuticals IncBayer HealthCare Pharmaceuticals Inc is the sponsor of the trial
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None